Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
about
Systems biology of cisplatin resistance: past, present and futureDNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapyCytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Protein Profiling of Bladder Urothelial Cell CarcinomaVirtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interactionKRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cellsPlatinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder CancerAdjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.Recent advances in treatment of advanced urothelial carcinoma.Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.DNA Repair Pathway Alterations in Bladder Cancer.A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma.MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapyERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapyERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapyBiomarkers for bladder cancer management: present and future.Evaluation of cell proliferation, apoptosis, and DNA-repair genes as potential biomarkers for ethanol-induced CNS alterations.The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.Novel agents for advanced bladder cancer.Current therapeutic strategies for invasive and metastatic bladder cancer.The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to ChemoradiotherapyPrognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapyBiomarkers for prognosis and treatment selection in advanced bladder cancer patients.Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.Correlation Analysis and Prognostic Impact of (18)F-FDG PET and Excision Repair Cross-Complementation Group 1 (ERCC-1) Expression in Non-Small Cell Lung Cancer.Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancerTumor-related gene expression levels in pulmonary pleomorphic carcinoma.Progress in personalizing chemotherapy for bladder cancerERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.Biomarker development in the context of urologic cancersPersonalized therapy for urothelial cancer: review of the clinical evidence.Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancerγ-secretase inhibition combined with cisplatin enhances apoptosis of nasopharyngeal carcinoma cellsPharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.Factors affecting platinum sensitivity in cervical cancer
P2860
Q26863585-6D8787BA-8CC2-439A-842C-D1A2CDD65284Q27022940-D43A4861-E88F-49ED-A9E6-1D816D8BC7E3Q27026717-90D5D898-D44B-495A-9359-C690930AF0AFQ27324419-14AD1B66-8C99-470C-8F96-6576717B0487Q28484387-76801311-6C17-4F9D-BC0E-E591475D4293Q28485355-52DAAFF7-685F-443B-8B1A-86DAFD9723BDQ28552143-9CE338CF-D5AF-4C4C-9E11-94060BA679A0Q33396809-D4DDDF2E-9CB0-4C18-9E0A-515B5314201DQ33565845-697CD4AA-AC8E-4D52-94B8-CD20098ECBBBQ33578400-5DDC4561-2A3A-4773-A126-DB6F3E03240AQ33607945-DA8274AB-A904-4783-9F0B-69B520209472Q33621281-A5149725-A567-457A-9EAB-5143AA2089D0Q33651005-B8A26432-EC0F-4707-9095-605E5D7D2730Q33903723-E4996645-833F-4059-BC5F-4BB4B7A1FDEAQ34143862-D5143BA3-13D9-4801-B2C1-10B854011C48Q34256001-55A21C34-1282-42D2-ADC4-5F4DF9263E8AQ34278209-E1ED0A21-D824-4955-A6B8-8BC03843474BQ34448168-F491439B-061C-432E-987B-A0B7DDF3DCE1Q34456950-2BE73BD5-0684-4EDA-B6E9-EB3412C5A692Q34465835-18D6A8F1-28A6-421C-80CD-D5D42B73E0F8Q35076184-1BC3A6DD-380F-43AE-A92F-E2C4509EA61CQ35128721-B8D88D54-E782-43F2-957B-1D0F6337312FQ35175390-7E316587-C5F1-4285-8156-23B0944A6E99Q35495280-5F6CBA80-74F7-4113-80B4-401F95910462Q35510634-D1D09B06-D78E-4EBE-8C92-73E7DAA93533Q35554515-C349B891-4BC7-4B6D-B325-8199B0DAAB6CQ35667815-3A20AB78-A738-4E7A-AA8C-ECBD4CADCFDEQ35671292-ABE1F9DC-2589-41A5-BB2E-DDFEB699374AQ35705620-E8021154-A63D-4928-B824-DF40758DCD40Q35724916-CBE8DDA3-AF51-4CA5-BB99-0B60982FA8C1Q35730375-DF550AD2-DA3B-43DF-B777-10BE0D6BCA3FQ35734083-0954F791-0BE4-42D6-88A5-58C767DE4A11Q35779460-C34D18E6-6162-4BD4-BB83-28A3E69E2ECFQ35833376-7D2B7213-6A76-4DA5-A3F4-7D874A7BA9C8Q35906352-C2804FAC-8D5E-41AA-9995-E5D5B953992AQ36062762-A0BB77ED-4D75-44EE-85F0-5DDBD152EACAQ36099310-E7A3CE7A-2554-4B77-B8C6-7B4C39AB423EQ36224427-F9BBBD55-566A-4694-97CF-733A2089D323Q36328010-59E2C170-247D-474E-B96A-AE232BF597FAQ36336472-B52FFFA2-ACC1-4EF7-B1A0-0CDF4B127DB2
P2860
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@ast
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@en
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@nl
type
label
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@ast
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@en
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@nl
prefLabel
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@ast
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@en
Gene expression of ERCC1 as a ...... cisplatin-based chemotherapy.
@nl
P2093
P356
P1433
P1476
Gene expression of ERCC1 as a ...... g cisplatin-based chemotherapy
@en
P2093
F L Cecere
J Bellmunt
J J de la Cruz
L Paz-Ares
P304
P356
10.1093/ANNONC/MDL435
P577
2007-01-17T00:00:00Z